The potential reclassification of cannabinoids, particularly at the federal level, is generating considerable buzz within the sector. A shift away from Schedule I status, often considered as outdated and website hindering progress, could unlock significant opportunities for companies. Reduced regulatory burdens, alongside greater access to banking